Speaker(s): 

Sara Waqar, MD, Resident Physician, Geisinger - has nothing to disclose.

Nicole Anderson, DO, Resident Physician, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Pathology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Analyze the pathological features of benign and malignant Inflammatory Myofibroblastic Tumors (IMT)
• Explain the significance of using p16 IHC as a prognostic tool in IMTs 
• Recommend cytology, FISH, and DNA methylation tests as they pertain to diagnosing urinary tract carcinomas
• Critique updates to the Paris classification system for upper urinary tract carcinoma

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Zachary S. Hoffer, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session: 

None.